Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 3c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.40), $0.03 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $552.72 thousand.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Hyperscale Data launches $300M at-the-market stock offering
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy